Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018)
Avalo Therapeutics' (AVTX) quarterly Asset Writedowns and Impairment came in at $38438.0 in Q4 2018, down 75.93% on a QoQ basis from $159687.0 in Q3 2018.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018) Analysis & Trends
Avalo Therapeutics (AVTX) has 1 years of Asset Writedowns and Impairment data on file, last reported at $38438.0 in Q4 2018.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $38438.0 in Q4 2018, while the trailing twelve-month figure through Sep 2020 was $38438.0 (down 97.98% YoY) and the FY2019 annual result came in at $1.4 million, down 23.73% from the prior year.
- Asset Writedowns and Impairment slipped to $38438.0 in Q4 2018, from $159687.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.7 million in Q2 2018 to a low of $38438.0 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 38,438.00 |
| Sep 30, 2018 | 159,687.00 |
| Jun 30, 2018 | 1.70 Mn |